Novo, Lilly's shares drop as Trump vows weight-loss drug price cuts

Shares of major weight-loss drug manufacturers, including Novo Nordisk and Eli Lilly, fell sharply after President Trump announced that the price of Novo's Ozempic treatment would be significantly reduced, potentially to $150. This declaration, made in the context of the administration's 'most favored nation' drug pricing policy, has heightened investor concerns about potential widespread price cuts in the lucrative obesity treatment market and could establish a precedent for future drug launches, despite ongoing negotiations and the uncertainty surrounding the final price point.

Analysis

President Trump's announcement regarding a potential price reduction for Novo Nordisk's Ozempic to $150 from its current list price of $1,000 (or $499 cash price) triggered a significant market reaction. Shares of Novo Nordisk (NVO) fell 6.3%, while Eli Lilly (LLY) dropped over 3%, and other obesity drug developers like Zealand Pharma and Viking Therapeutics also saw declines of nearly 7% and 2% respectively. This reflects investor concern over the "worst-case scenario" for the lucrative obesity drug market.

The proposed price cut aligns with the administration's "most favored nation" policy, aiming to equalize U.S. drug prices with those in other wealthy nations. However, the finality of the $150 price is uncertain, with Bernstein analyst Courtney Breen viewing Trump's comment as a "negotiating lever" rather than a definitive outcome. Both Novo Nordisk and Eli Lilly confirmed ongoing discussions with the administration regarding the "most favored nation" order, and CMS negotiations for GLP-1 class drugs are not yet complete.

This development could establish a significant precedent for future oral obesity drug launches, potentially limiting price differentials across the industry. While the market reacted strongly, UBS analysts indicated they had already factored potential U.S. price cuts into their forecasts, suggesting the mentioned prices might be "more than captured by our numbers." The overall sentiment is strongly negative and uncertain, highlighting the regulatory risk now facing the healthcare sector.

Key Decisions for Investors

• Closely monitor the ongoing negotiations between drugmakers and the U.S. administration regarding the "most favored nation" policy and GLP-1 drug pricing, as the $150 price for Ozempic is not yet finalized and represents a significant downside risk.
• Re-evaluate valuation models for companies with substantial exposure to the obesity drug market, such as Novo Nordisk and Eli Lilly, to account for potential future price compression and increased regulatory intervention.
• Consider portfolio adjustments or hedging strategies to mitigate exposure to the healthcare sector, particularly the GLP-1 segment, given the heightened regulatory uncertainty and strongly negative market sentiment.